Physician profile
Kelsea Lambert
NPI 1184394397
$1,275.55
in general payments reported to CMS, 2019-2025
23 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $547 · 2023: $315 · 2024: $169 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $728.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $163.72 | 2023-2025 | Cologuard Collection Kit |
| Galderma Laboratories, L.P. | $144.92 | 2025 | |
| Lilly USA, LLC | $143.59 | 2022-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $130.49 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $123.34 | 2022-2024 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $100.22 | 2022 | |
| Abbvie INC. | $62.53 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.66 | 2022-2023 | |
| Corium, LLC | $43.17 | 2022-2024 | Azstarys |
| Lundbeck LLC | $42.24 | 2022 | |
| Novartis Pharmaceuticals Corporation | $38.23 | 2023 | |
| Alnylam Pharmaceuticals INC. | $31.88 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.33 | 2022-2023 | Trintellix |
| Alexion Pharmaceuticals, INC. | $22.08 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.57 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $17.54 | 2023 | Tlando, Xyosted, Nocdurna |
| Axsome Therapeutics, INC. | $17.20 | 2023 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $16.61 | 2022 | |
| Glaxosmithkline, LLC. | $16.42 | 2023 | Trelegy Ellipta |
| Nestle Healthcare Nutrition INC. | $14.64 | 2023 | |
| Dexcom, INC. | $14.30 | 2022 | |
| Amarin Pharma, INC. | $13.04 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsea Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.